Jump to content

Alimta trials for treatment of extensive sclc

Recommended Posts


Lilly Begins Alimta Lung Cancer Study

© 2006 The Associated Press

INDIANAPOLIS — Drug maker Eli Lilly and Co. said Friday it started what promises to be the largest clinical trial studying a form of quick-spreading lung cancer.

The company hopes to see whether its cancer drug Alimta will be effective in treating extensive-stage small cell lung cancer, a form of the disease that spreads rapidly and accounts for about 15 percent to 20 percent of all lung cancers.

Alimta is already approved by the Food and Drug Administration to treat mesothelioma, a rare form of lung cancer caused by asbestos exposure, and non-small cell lung cancer, the most common form of lung cancer.

Lilly plans to enroll about 1,820 patients with extensive-stage SCLC and give one group Alimta combined with the chemotherapy carboplatin and the other group the chemotherapies etoposide and carboplatin.

The primary endpoint of the trial will be to compare how long the treatments extend patient survival.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.